JP2024109576A5 - - Google Patents

Download PDF

Info

Publication number
JP2024109576A5
JP2024109576A5 JP2024068916A JP2024068916A JP2024109576A5 JP 2024109576 A5 JP2024109576 A5 JP 2024109576A5 JP 2024068916 A JP2024068916 A JP 2024068916A JP 2024068916 A JP2024068916 A JP 2024068916A JP 2024109576 A5 JP2024109576 A5 JP 2024109576A5
Authority
JP
Japan
Prior art keywords
fimh
polypeptide
seq
lectin domain
polypeptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024068916A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024109576A (ja
Filing date
Publication date
Priority claimed from PCT/IB2022/050166 external-priority patent/WO2022153166A1/en
Application filed filed Critical
Publication of JP2024109576A publication Critical patent/JP2024109576A/ja
Publication of JP2024109576A5 publication Critical patent/JP2024109576A5/ja
Pending legal-status Critical Current

Links

JP2024068916A 2021-01-12 2024-04-22 FimH変異体、それを含む組成物、及びその使用 Pending JP2024109576A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21151126 2021-01-12
EP21151126.6 2021-01-12
PCT/IB2022/050166 WO2022153166A1 (en) 2021-01-12 2022-01-11 Fimh mutants, compositions therewith and use thereof
JP2023541784A JP7532672B2 (ja) 2021-01-12 2022-01-11 FimH変異体、それを含む組成物、及びその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023541784A Division JP7532672B2 (ja) 2021-01-12 2022-01-11 FimH変異体、それを含む組成物、及びその使用

Publications (2)

Publication Number Publication Date
JP2024109576A JP2024109576A (ja) 2024-08-14
JP2024109576A5 true JP2024109576A5 (cg-RX-API-DMAC7.html) 2025-01-20

Family

ID=74175646

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023541784A Active JP7532672B2 (ja) 2021-01-12 2022-01-11 FimH変異体、それを含む組成物、及びその使用
JP2024068916A Pending JP2024109576A (ja) 2021-01-12 2024-04-22 FimH変異体、それを含む組成物、及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023541784A Active JP7532672B2 (ja) 2021-01-12 2022-01-11 FimH変異体、それを含む組成物、及びその使用

Country Status (12)

Country Link
US (3) US11725028B2 (cg-RX-API-DMAC7.html)
EP (1) EP4277921A1 (cg-RX-API-DMAC7.html)
JP (2) JP7532672B2 (cg-RX-API-DMAC7.html)
KR (2) KR102746713B1 (cg-RX-API-DMAC7.html)
CN (1) CN116888140A (cg-RX-API-DMAC7.html)
AR (1) AR124604A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022207740B2 (cg-RX-API-DMAC7.html)
CA (1) CA3207841A1 (cg-RX-API-DMAC7.html)
IL (1) IL303954B2 (cg-RX-API-DMAC7.html)
MX (1) MX2023008251A (cg-RX-API-DMAC7.html)
TW (1) TW202241929A (cg-RX-API-DMAC7.html)
WO (1) WO2022153166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途
EP4448002A1 (en) * 2021-12-17 2024-10-23 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドa単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
AU743114B2 (en) 1997-04-01 2002-01-17 Corixa Corporation Aqueous immunologic adjuvant compositions of monophosphoryl lipid A
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
JP2003505030A (ja) * 1999-07-15 2003-02-12 メディミューン,インコーポレーテッド FimHアドヘジンベイストワクチン
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
AU2001271907A1 (en) 2000-07-07 2002-01-21 Medimmune, Inc. FimH adhesin proteins and methods of use
EP1313502A4 (en) * 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
WO2002102974A2 (en) * 2000-12-08 2002-12-27 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN101019123A (zh) * 2004-02-06 2007-08-15 科学与工业研究委员会 用于识别有治疗潜力的粘附素和粘附素样蛋白的计算方法
CN101355928B (zh) 2005-04-26 2013-05-22 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和方法
ES2535084T3 (es) 2005-05-11 2015-05-05 Eth Zurich Proteínas N-glicosiladas recombinantes procedentes de células procariotas
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
SI2257307T1 (sl) 2008-02-20 2018-09-28 Glaxosmithkline Biologicals S.A. Biokonjugati, izdelani iz rekombinantnih N-glikoziliranih proteinov iz prokariontskih celic
CA2764374C (en) 2009-06-05 2019-11-19 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
CU24377B1 (es) 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
US10722580B2 (en) * 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
CN107847580B (zh) 2015-07-07 2022-08-12 扬森疫苗与预防公司 针对rsv的疫苗
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019048871A1 (en) * 2017-09-08 2019-03-14 The University Of Bristol PROTEIN ADMINISTRATION TO MEMBRANES
TW201946650A (zh) * 2018-03-12 2019-12-16 美商詹森藥物公司 針對腹內感染之疫苗
WO2021123360A1 (en) * 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
CN116888140A (zh) 2021-01-12 2023-10-13 杨森制药公司 FimH突变体、其组合物及其用途

Similar Documents

Publication Publication Date Title
FI4090363T3 (fi) FimH-mutantti, sen koostumuksia ja sen käyttö
Bensch et al. hBD‐1: a novel β‐defensin from human plasma
AU2016289492B2 (en) Vaccine against RSV
JP2018171063A5 (cg-RX-API-DMAC7.html)
JP2002523517A5 (cg-RX-API-DMAC7.html)
JP2024528407A5 (cg-RX-API-DMAC7.html)
JP2006149365A5 (cg-RX-API-DMAC7.html)
JP2023518596A5 (cg-RX-API-DMAC7.html)
CN117821427A (zh) 一种新型内溶素多肽
JP2023528207A5 (cg-RX-API-DMAC7.html)
JP6745720B2 (ja) 改変されたkz144エンドリシン配列
CN107312080B (zh) 一种来源于gsdmd蛋白的抗菌肽及其应用
JP2016537979A5 (cg-RX-API-DMAC7.html)
JP2019534884A5 (cg-RX-API-DMAC7.html)
IL303954B2 (en) FIMH mutants, their compositions and uses
Ryge et al. Novel lysine‐peptoid hybrids with antibacterial properties
Li et al. Molecular cloning, expression and characterization of the porcine β defensin 2 in E. coli
JP2005511038A5 (cg-RX-API-DMAC7.html)
JP2004505640A5 (cg-RX-API-DMAC7.html)
JP2004504815A (ja) 抗リステリアバクテリオシン
WO2006046239B1 (en) A thymus-specific protein
CN113549137B (zh) 一种靶向革兰氏阴性菌的富脯氨酸抗菌肽Pyr-2及其制备方法与应用
JP2008517998A5 (cg-RX-API-DMAC7.html)
JP2023544300A5 (cg-RX-API-DMAC7.html)
TW200716166A (en) Lawsonia intracellularis immunological proteins